retatrutide diabetes trial produces up to 30.3% weight loss in Phase 3 The data just dropped —

Living Well With Semaglutide Headaches from semaglutide are common, but they dont have to derail your progress

Nobody is talking about whats disappearing along with the fat

cerebral metabolic rate for glucose

Files Download Full Text (382 KB) Description Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant clinical benefit in managing diabetes mellitus type 2 (DM2), facilitating chronic weight loss, and potentially improving obstructive sleep apnea

Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, orforglipron and semaglutide used in the clinic are monoGLP-1RAs, tirzepatide acts not only on GLP1R, but also on glucose-dependent receptors of insulinotropic peptide (GIP), and retatrutide is a triple agonist of GLP-1, GIP and glucagon receptors